Author details

Nuri Faruk Aykan<sup>1</sup> \*, Mehmet Artac<sup>2</sup> and Tahsin Özatli<sup>1</sup>

\*Address all correspondence to: nfaruk@mac.com

1 Department of Medical Oncology, Bahcesehir Liv Hospital, Istinye University, Istanbul, Turkey

2 Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

## References


[7] Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—Viewpoint of the IARC working group. The New England Journal of Medicine. 2016;375:794-798

hyperglycemia, and to the development of type 2 diabetes which are the components of metabolic syndrome. Chronic low-grade inflammation is a hallmark of obesity, and obesity supports many hallmarks of carcinogenesis. It is clear that one of the consequences of metabolic syndrome is the increased risk of carcinogenesis. Targeting obesity and metabolic syn-

drome should be beneficial in the prevention and the treatment of colorectal cancer.

\*, Mehmet Artac<sup>2</sup> and Tahsin Özatli<sup>1</sup>

2012. CA: a Cancer Journal for Clinicians. 2015;65(2):87-108

Cancer Epidemiology, Biomarkers & Prevention. 2009;18:1688-1694

miology of Cancer. Switzerland: Springer; 2017. pp. 391-407

1 Department of Medical Oncology, Bahcesehir Liv Hospital, Istinye University, Istanbul,

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics,

[2] Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. Journal of the National Cancer

[3] Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates.

[4] Durko L, Malecka-Panas E. Lifestyle modifications and colorectal cancer. Current Colo-

[5] Keum N, Giovannucci EL. Epidemiology of colorectal cancer. In: Pathology and Epide-

[6] World Cancer Research Fund. Continuous update Project Report: Diet, Nutrition, Physical Activity and Colorectal Cancer: WCRF; 2017. wcrf.org/colorectal-cancer-2017

2 Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan

Conflict of interest

88 Body-mass Index and Health

Author details

Nuri Faruk Aykan<sup>1</sup>

University, Konya, Turkey

Institute. 1968;40:43-68

rectal Cancer Reports. 2014;10:45-54

Turkey

References

Authors declare no conflict of interest.

\*Address all correspondence to: nfaruk@mac.com


[21] Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-578

[36] Frystyk J, Vestbo E, Skjaerbaek C, et al. Free insulin-like growth factors in human obesity.

Body Mass Index and Colorectal Cancer http://dx.doi.org/10.5772/intechopen.78617 91

[37] Nam SY, Lee EJ, Kim KR, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. International Journal of Obesity and Related Metabolic

[38] Ricart W, Fernández-Real JM. No decrease in free IGF-I with increasing insulin in

[39] Wolk K, Larsson SC, Vessby B, et al. Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1879-1884

[40] Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. Journal of the

[41] Shimizu N, Nagata C, Shimizu H, et al. Height, weight, and alcohol consumption in relation to the risk of colorectal cancer in Japan: A prospective study. British Journal of

[42] Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Jour-

[43] Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer

[44] Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulinlike growth factor binding protein 3, and risk of colorectal cancer: A prospective study in

[45] Dev R, Bruera E, Dalal S. Insulin resistance and body composition in cancer patients.

[46] Sipos F, Székely H, Kis ID, et al. Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer. World Journal of Gastroenterology. 2017;23(46):8109-8119

[47] Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and pro-

[48] Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. The Journal of Biological Chemistry. 2002;277:39684-39695

[49] Hagiwara A, Nishiyama M, Ishizaki S. Branched-chain amino acids prevent insulininduced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. Journal of Cellular Physiology. 2012;227(5):2097-2105

obesity-related insulin resistance. Obesity Research. 2001;9:631-636

Metabolism. 1995;44:37-44

Disorders. 1997;21:355-359

Cancer. 2003;88:1038-1043

National Cancer Institute. 2002;94:972-980

nal of the National Cancer Institute. 1999;91, 5:620

northern Sweden. Gut. 2002;50:642-646

Annals of Oncology. 2018;29(suppl\_2):ii18-ii26

Epidemiology, Biomarkers & Prevention. 2000;9:345-349

posed mechanisms. Nature Reviews. Cancer. 2004;4(8):579-591


[36] Frystyk J, Vestbo E, Skjaerbaek C, et al. Free insulin-like growth factors in human obesity. Metabolism. 1995;44:37-44

[21] Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;

[22] Swinburn B, Sacks G, Ravussin E. Increased food energy supply is more than sufficient to explain the US epidemic of obesity. The American Journal of Clinical Nutrition. 2009;90:

[23] Samson SL, Garber AJ. Metabolic syndrome. Endocrinology and Metabolism Clinics of

[24] Nunez et al. Physical activity, obesity and sedentary behaviour and the risks of colon and

[25] Stone TW, McPherson M, Darlington LG. Obesity and Cancer: Existing and new hypoth-

[26] Kahn BB, Flier JS. Obesity and insulin resistance. The Journal of Clinical Investigation.

[27] Hsing AW, Chua S, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: A population-based study. Journal of the National Cancer Institute. 2001;93:783-789

[28] Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. Journal of Clinical Oncology. 2002;

[29] Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of

[30] Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. Journal of the

[31] Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in

[32] Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. Journal of the National Cancer Institute. 1999;91:

[33] Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. Journal of the National Cancer Institute. 2004;96:546-553

[34] Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospec- tive investigation into Cancer and

[35] Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-

nutrition. International Journal of Cancer. 2007;121:368-376

analysis. Journal of the National Cancer Institute. 2005;97:1679-1687

women. Cancer Epidemiology, Biomarkers & Prevention. 2005a;14:850-855

rectal cancers in the 45 and up study. BMC Public Health. 2018;18:325

eses for a causal connection. eBioMedicine. 2018;30:14-28

insulin resistance. Diabetes Care. 2004;27:1998-2002

National Cancer Institute. 2000;92:1592-1600

371:569-578

90 Body-mass Index and Health

1453-1456

2000;106:473-481

20:42-51

1147-1154

North America. 2014;43:1-23


[50] Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. The Journal of Clinical Investigation. 1990;86: 1503-1510

[64] Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase and Akt. Molecular and Cellular Biology. 1997;

[65] Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using

[66] Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, et al. Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated che- motaxis, VEGF secretion and proliferation of multiple myeloma cells: Study in the 5T33MM

[67] André F, Rigot V, Thimonier J, et al. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. International Journal of Cancer. 1999;83:497-505

[68] Bordonaro M, Lazarova D. Hypothesis: Obesity is associated with a lower mutation

[69] Brändstedt J, Wangefjord S, Nodin B, Eberhard J, Sundström M, Manjer J, et al. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colo-

[71] Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011 Mar 4;

[72] Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. The Journal of Clinical

[73] Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. International Journal of Obesity and Related Metabolic Disorders.

[74] Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adi- pocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:

[75] Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543-546

[76] Stattin P, Palmqvist R, Soderberg S, et al. Plasma leptin and colorectal cancer risk: A prospective study in northern Sweden. Oncology Reports. 2003;10:2015-2021

[77] Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: Does leptin provide a link? International Journal of Cancer. 2004;109:149-152

[78] Tamakoshi K, Toyoshima H, Wakai K, et al. Leptin is associated with an increased female colorectal cancer risk: A nested case-control study in Japan. Oncology. 2005;68:454-461

rectal cancer in men and women: A cohort study. PLoS One. 2014;9(6):e98964 [70] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70

threshold in colon cancer. Journal of Cancer. 2015 Jul 15;6(9):825-831

Endocrinology and Metabolism. 2004 Jun;89(6):2548-2556


Body Mass Index and Colorectal Cancer http://dx.doi.org/10.5772/intechopen.78617 93

17:1595-1606

144(5):646-674

2003;27:875-888

2273-2282

the phosphatidylinositol 3<sup>0</sup>

Journal of Biological Chemistry. 1997;272:154-161

model. British Journal of Cancer. 2004;90:1076-1083


[64] Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase and Akt. Molecular and Cellular Biology. 1997; 17:1595-1606

[50] Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. The Journal of Clinical Investigation. 1990;86:

[51] Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Research. 2002;62:

[52] Alemán JO, Eusebi LH, Ricciardiello L, Patidar K, Sanyal AJ, Holt PR. Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology. 2014;146:357-373

[53] Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Human Pathology. 2003;34:803-808

[54] Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins.

[55] LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer

[56] Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP)

[57] Massoner P, Ladurner-Rennau M, Eder IE, Klocker H. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer.

[58] Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: New twists in the

[59] Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine

[60] Zhang B, Roth RA. The insulin receptor-related receptor. Tissue expression, ligand binding specificity, and signaling capabilities. The Journal of Biological Chemistry. 1992;267:

[61] Du Y, Wei T. Inputs and outputs of insulin receptor. Protein & Cell. 2014;5(3):203-213

[62] Myers MG, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J, et al. Insulin receptor

[63] Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:

insulin-like growth factor-1, and interleukin-4 stimulation. The Journal of Biological


1503-1510

92 Body-mass Index and Health

2942-2950

Endocrine Reviews. 2002;23:824-854

superfamily. Endocrine Reviews. 1999;20:761-787

substrate-1 mediates phosphatidylinositol 3<sup>0</sup>

Chemistry. 1994;269:28783-28789

British Journal of Cancer. 2010 Nov 9;103(10):1479-1484

tale. Nature Reviews. Molecular Cell Biology. 2003;4:202-212

Letters. 2003;195:127-137

Reviews. 2009;30:586-623

18320-18328

231-241


[79] Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121:79-90

[92] Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-

Body Mass Index and Colorectal Cancer http://dx.doi.org/10.5772/intechopen.78617 95

[93] Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

[94] Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science. 1993;259:87-91

[95] Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflamma-

[96] Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: Adipose inflammation as a mediator of obesity-associated cancer. Clinical Cancer Research. 2013;

[97] Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: Local and systemic mech-

[98] Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prevention Research. 2013;6:

[99] Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo 1. The

[100] Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Research. 2008;68:

[101] Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt path- way and regulates cyclin A1 to promote prostate cancer cell survival. International Journal of

[102] Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a

[103] Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR, et al. STAT3 acti- vation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF recep- tor. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:

[104] Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmunity Reviews.

2009;8:379-383 [PMID: 19105984]. DOI: 10.1016/j.autrev.2008.12.002

Journal of Clinical Endocrinology and Metabolism. 1997;82:4196-4200

associated cancer. Cancer Cell. 2009;15:103-113

tory bowel disease. Cancer. 2001;91:854-862

19:6074-6083

428-436

323-328

16975-16980

Cancer. 2008;122:1521-1529

The Journal of Clinical Investigation. 1995;95:2409-2415

anisms. Annual Review of Medicine. 2015;66:297-309

highly conserved enhancer. Blood. 2007;110:1330-1333


[92] Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer. Cancer Cell. 2009;15:103-113

[79] Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121:79-90

[80] Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). The Journal of

[81] Tandon K, Imam M, Ismail BE, Castro F. Body mass index and colon cancer screening: The road ahead. World Journal of Gastroenterology. 2015 Feb 7;21(5):1371-1376. DOI:

[82] Endo H, Hosono K, Uchiyama T, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut.

[83] Comstock SS, Hortos K, Kovan B, McCaskey S, Pathak DR, Fenton JI. Adipokines and obesity are associated with colorectal polyps in adult males: A cross-sectional study.

[84] Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, Potter JD. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiology, Biomarkers & Prevention. 2007;16:2697-2703 [PMID: 18086776].

[85] Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical

[86] Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. Journal of the National

[87] Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein

[88] Yamauchi T, Kamon J, Minokoshi YA, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated pro-

[89] Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int. Journal of

[90] Jain R, Austin Pickens C, Fenton JI. The role of the lipidome in obesity-mediated colon

[91] Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200 [PMID: 12746274]. DOI: 10.1210/en.2003-0285

cancer risk. The Journal of Nutritional Biochemistry. 2018;59:1-9

Acrp30 enhances hepatic insulin action. Nature Medicine. 2001;7:947-953

PLoS One. 2014;9:e85939 [PMID: 24465801]. DOI: 10.1371/journal.pone.0085939

2011;60:1363-1371 [PMID: 21406387]. DOI: 10.1136/gut.2010.235754

Biological Chemistry. 2006;281:26320-26328

DOI: 10.1158/1055-9965.EPI-07-0467

Cancer Institute. 2005;97:1688-1694

Oncology. 2009;34:339-344

Research Communications. 1999;257:79-83

tein kinase. Nature Medicine. 2002;8:1288-1295

10.3748/wjg.v21.i5.1371

94 Body-mass Index and Health


[105] Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. International Journal of Oncology. 2012;40:560-566. DOI: 10.3892/ijo.2011.1247]

[119] Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance.

Body Mass Index and Colorectal Cancer http://dx.doi.org/10.5772/intechopen.78617 97

[120] Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. American Journal of Physiology. Endocrinology and Metabolism.

[121] Cao L, Choi EY, Liu X, Martin A, Wang C, Xu X, During MJ. White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-

[122] Connolly E, Morrisey RD, Carnie JA. The effect of interscapular brown adipose tissue removal on body-weight and cold response in the mouse. The British Journal of Nutri-

[123] van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-activated brown adipose tissue in healthy

[124] Nisoli E, Briscini L, Giordano A, Tonello C, Wiesbrock SM, Uysal KT, Cinti S, Carruba MO, Hotamisligil GS. Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proceedings of the National

[125] Murano I, Barbatelli G, Parisani V, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. Journal of Lipid

[126] Hanyuda A, Cao Y, Hamada T, et al. Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status. European Journal of Epidemiology.

[127] Beyaz S, Mana MD, Roper J, et al. High-fat diet enhances stemness and tumorigenicity of

[128] Wang D, Fu L, Ning W, Guo L, Sun X, Dey SK, Chaturvedi R, Wilson KT, DuBois RN. Peroxisome proliferator-activated receptor d promotes colonic inflammation and tumor growth. Proceedings of the National Academy of Sciences of the United States of America.

[129] Hoffmeister M, Bläker H, Kloor M, Roth W, Toth C, Herpel E, et al. Body mass index and microsatellite instability in colorectal cancer: A population-based study. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(12):2303-2311. DOI: 10.1158/1055-9965.EPI-

[130] Semenkovich CF. Regulation of fatty acid synthase (FAS). Progress in Lipid Research.

[131] Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Human Pathology. 2007;38(6):842-849

13-0239. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24127414

men. The New England Journal of Medicine. 2009;360:1500-1508

Academy of Sciences of the United States of America. 2000;97:8033-8038

Physiological Reviews. 2004;84:277-359

adipocyte axis. Cell Metabolism. 2011;14:324-338

2017;32:393-407. DOI: 10.1007/s10654-017-0254-y

intestinal progenitors. Nature. 2016;531(7592):53-58

2007;293:E444-E452

tion. 1982;47:653-658

Research. 2008;49:1562-1568

2014;111(19):7084-7089

1997;36:43-53


[119] Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiological Reviews. 2004;84:277-359

[105] Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. International Journal of

[106] Il'yasova D, Colbert LH. Harris, et al. circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol.

[107] Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochimica et Biophysica Acta. 2014;

[108] Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertension

[109] West M. Dead adipocytes and metabolic dysfunction: Recent progress. Current Opinion

[110] Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity- induced adipose tissue macrophage infiltration and insulin resistance in mice. The Journal of

[111] Bertola A, Deveaux V, Bonnafous S, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

[112] Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human

[113] Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-

[114] Lusis AJ, Attie AD, Reue K. Metabolic syndrome: From epidemiology to systems biology.

[115] Jiang Y, Pan Y, Rhea PR, et al. A sucrose-enriched diet promotes tumorigenesis in mammary gland in part through the 12-lipoxygenase pathway. Cancer Research. 2016;

[116] Rogero MM, Calder PC. Obesity, inflammation, toll-like receptor 4 and fatty acids.

[117] Ramos-Nino ME. The role of chronic inflammation in obesity-associated cancers. ISRN

[118] Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham heart

induced colon cancer progression. Carcinogenesis. 2009;30:690-697

Oncology. 2012;40:560-566. DOI: 10.3892/ijo.2011.1247]

in Endocrinology, Diabetes, and Obesity. 2009;16:178-182

Biomark. Prevention. 2005;14:2413-2418

Clinical Investigation. 2007;117:2877-2888

obese subjects. Diabetologia. 2003;46:1483-1488

Nature Reviews. Genetics. 2008;9(11):819-830

1842:446-462

96 Body-mass Index and Health

Research. 2008;31:1283-1291

Diabetes. 2009;58:125-133

76:24-29

Nutrients. 2018;10(4)

Oncology. 2013;2013:697521

study. Circulation. 2007 Jul 3;116(1):39-48


[132] Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. The American Journal of Pathology. 1997; 150:201-208

[145] Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immuno-

Body Mass Index and Colorectal Cancer http://dx.doi.org/10.5772/intechopen.78617 99

[146] Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. Journal of the National Cancer Institute.

[147] Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer.

[148] Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and leukemia group B 89803. Journal of Clinical Oncology.

[149] Zafar Y, Hubbard J, Van Cutsem E, et al. Survival Outcomes According to Body Mass Index (BMI): Results from a Pooled Analysis of 5 Observational or Phase IV Studies of Bevacizumab in Metastatic Colorectal Cancer (mCRC). Barcelona: ESMO World Con-

[150] Kasi PM, Zafar SY, Grothey A. Is obesity an advantage in patients with colorectal cancer? Expert Review of Gastroenterology & Hepatology. 2015;9:1339-1342. DOI: 10.1586/

[151] Simkens LH, Koopman M, Mol L, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted

[152] Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colo-

[153] Aykan NF, Yildiz I, Sen F, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Medical Oncology. 2013;30(3):679. DOI: 10.1007/

[154] Patel GS, Ullah S, Beeke C, et al. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer

[155] Artac M, Korkmaz L, Coskun HS, et al. Bevacuzimab may be less effective in obese metastatic colorectal Cancer patients. Journal of Gastrointestinal Cancer. 2018 Jan 4.

2008;26:4109-4115. DOI: 10.1200/JCO.2007.15.6687

therapy. European Journal of Cancer. 2011;47:2560-2567

Medicine. 2015;4(10):1461-1471. DOI: 10.1002/cam4.490

gress on Gastrointestinal Cancer; 2015

rectal cancer. Gut. 2010;59:341-347

DOI: 10.1007/s12029-017-0047-2

17474124.2015.1089170

s12032-013-0679-4

therapy. 2014;63:721-735

2006;98:1647-1654

2013;119:1528-1536


[145] Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy. 2014;63:721-735

[132] Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. The American Journal of Pathology. 1997;

[133] Visca P, Alo PL, Del Nonno F, et al. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clinical Cancer

[134] Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous

[135] Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. The American Journal of

[136] Haydon AMM, Jass JR. Emerging pathways in colorectal-cancer development. The Lan-

[137] Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-Positive colon cancer. Cancer Research. 2001;61:

[138] Pyne NJ, Pyne S. Sphingosine 1-phosphate is a missing link between chronic inflamma-

[139] Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB Journal: Official Publication of

[140] Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB Journal: Official Publication of the

[141] Phinney SD. Metabolism of exogenous and endogenous arachidonic acid in cancer. In: Heber, Kritchevsky, editors. Dietary Fats, Lipids, Hormones, and Tumorigenesis. New

[142] Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy.

[143] Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and

[144] Samad N, Yasmin F, Naheed S, Bari AZ, Ayaz MM, Zaman A, et al. Serum levels of leptin, zinc and tryptophan in obese subjects with sleep deficits. Pakistan Journal of

the Federation of American Societies for Experimental Biology. 2006;20:386-388

Federation of American Societies for Experimental Biology. 2009;23:405-414

150:201-208

98 Body-mass Index and Health

Research. 1999;5:4111-4118

component. Modern Pathology. 2006;19:59-68

Surgical Pathology. 2006;30(9):1175-1183

tion and colon cancer. Cancer Cell. 2013;23:5-7

York: Plenum Press; 1996. pp. 87-94

Pharmacological Reports. 2010;62:233-244

Pharmaceutical Sciences. 2017;30:1431-1438

insulin sensitivity. Cell Metabolism. 2010;12:593-605

cet Oncology. 2002;3(2):83-88

126-130

